Trebananib: all 29 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
• Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorCompletedNCT03239145Phase 1Results posted
• A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid TumorsCompletedNCT02525536Phase 1Results posted
• Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by SurgeryCompletedNCT01623869Phase 2Results posted
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedNCT01609790Phase 2Results posted
• AMG 386 and Abiraterone for Advanced Prostate CancerCompletedNCT01553188Phase 2Results posted
• Trebananib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT01210222Phase 2Results posted
• AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With SunitinibCompletedNCT00853372Phase 2Results posted
• AMG 386 Drug-Drug Interaction Study With PaclitaxelCompletedNCT01992341Phase 1
• Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial CarcinomaWithdrawnNCT01907308Phase 2
• Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung CancerCompletedNCT01666977Phase 1/2
• Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01555268Phase 1
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT01548482Phase 1
• Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System TumorsCompletedNCT01538095Phase 1
• TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian CancerTerminatedNCT01493505Phase 3
• A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal FunctionCompletedNCT01331941Phase 1
• Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian CancerCompletedNCT01253681Phase 1
• Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal CancerStatus unknownNCT01249521Phase 2
• TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube CancerCompletedNCT01204749Phase 3
• A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular CancerCompletedNCT00872014Phase 2
• To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.CompletedNCT00861419Phase 1
• Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerCompletedNCT00807859Phase 1
• AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CRCompletedNCT00770536Phase 1
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal CarcinomaCompletedNCT00752570Phase 2
• Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal AdenocarcinomaCompletedNCT00583674Phase 2
• Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer PatientsCompletedNCT00511459Phase 2
• Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal CancerCompletedNCT00479817Phase 2
• AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With SorafenibCompletedNCT00467025Phase 2
• Study Evaluating AMG 386 in Adult Patients With Advanced Solid TumorsCompletedNCT00102830Phase 1

← Trebananib overview